Journal ArticleDOI
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
Alice B. Gottlieb,Neil J. Korman,Kenneth B. Gordon,Steven R. Feldman,Mark Lebwohl,John Koo,Abby S. Van Voorhees,Craig A. Elmets,Craig L. Leonardi,Karl R. Beutner,Reva Bhushan,Alan Menter +11 more
Reads0
Chats0
TLDR
An overview of psoriasis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment is given.Abstract:
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment. Although patients with mild to moderate psoriatic arthritis may be treated with nonsteroidal anti-inflammatory drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant psoriatic arthritis. We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis.read more
Citations
More filters
Journal ArticleDOI
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E.M. Griffiths,Kristian Reich,Mark Lebwohl,Peter C.M. van de Kerkhof,Carle Paul,Alan Menter,Gregory S Cameron,J. Erickson,L. Zhang,Roberta J. Secrest,Susan Ball,Daniel K. Braun,Olawale Osuntokun,Michael P. Heffernan,Brian J. Nickoloff,Kim A. Papp +15 more
TL;DR: Two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis met the primary endpoints.
Journal ArticleDOI
Hidradenitis suppurativa: A comprehensive review
TL;DR: Hidradenitis suppurativa, also known as acne inversa, is a chronic, often debilitating disease primarily affecting the axillae, perineum, and inframammary regions and is considered a disease of follicular occlusion rather than an inflammatory or infectious process of the apocrine glands.
Journal ArticleDOI
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Alan Menter,Neil J. Korman,Craig A. Elmets,Steven R. Feldman,Joel M. Gelfand,Kenneth B. Gordon,Alice B. Gottlieb,John Koo,Mark Lebwohl,Henry W. Lim,Abby S. Van Voorhees,Karl R. Beutner,Reva Bhushan +12 more
TL;DR: The efficacy and safety, and recommendations for the use of the 3 most commonly used, and approved, traditional systemic agents: methotrexate, cyclosporine, and acitretin are discussed.
Journal ArticleDOI
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim A. Papp,Kristian Reich,Craig L. Leonardi,Leon H Kircik,Sergio Chimenti,Richard G. Langley,Chia Chi Hu,R. Stevens,Robert M. Day,Kenneth B. Gordon,Neil J. Korman,Christopher E.M. Griffiths +11 more
TL;DR: Apremilast was effective in moderate to severe plaque psoriasis and no new significant adverse events emerged with continued ap Remilast exposure versus the placebo-controlled period.
Journal ArticleDOI
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
Laure Gossec,Josef S. Smolen,Cécile Gaujoux-Viala,Zoe Ash,Helena Marzo-Ortega,D. van der Heijde,Oliver FitzGerald,Daniel Aletaha,Peter V. Balint,Dimitrios T. Boumpas,Jürgen Braun,F. C. Breedveld,G.-R. Burmester,Juan D. Cañete,M. de Wit,Hanne Dagfinrud,K. de Vlam,Maxime Dougados,P S Helliwell,A. Kavanaugh,Tore K Kvien,Robert Landewé,Thomas A. Luger,Mara Maccarone,Dennis McGonagle,Neil McHugh,Iain B. McInnes,Christopher T. Ritchlin,J. Sieper,Paul P. Tak,Guido Valesini,Jiri Vencovsky,Kevin L. Winthrop,Angela Zink,Paul Emery +34 more
TL;DR: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion.
References
More filters
Journal ArticleDOI
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
Journal ArticleDOI
Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use
Andrew Yule Finlay,G. K. Khan +1 more
TL;DR: This study confirmed that a topic eczema, psoriasis and generalized pruritus have a greater impact on quality of life than acne, basal cell carcinomas and viral warts.
Journal ArticleDOI
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
William J. Taylor,Dafna D. Gladman,Philip S. Helliwell,Antonio Marchesoni,Philip J. Mease,Herman Mielants +5 more
TL;DR: The CASPAR criteria are simple and highly specific but less sensitive than the Vasey and Espinoza criteria and are confirmed as the validity of clinical diagnosis as the gold standard definition of "case"-ness.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.